Эральфон

Quick links

Choose a section

Quick links to important sections

Advertisements

Эральфон

Selected form

Advertisements
Advertisements

Overview of Эральфон

Quick Facts

Property Description
Active ingredient Epoetin Alfa (INN)
Form Solution for injection (IV or SC)
Pharmacological class Erythropoiesis-Stimulating Agent (ESA)
Common use Counteracting anemia (low red blood cell count)
Origin Recombinant Biologic (Synthetic Human Protein)

What Type of Medicine is Эральфон and What is its Composition?

Эральфон is a specialized, prescription-only medication classified as an Erythropoiesis-Stimulating Agent (ESA), belonging to the larger group of Hematopoietic Growth Factors. The core active ingredient is Epoetin Alfa (INN). This medication is typically supplied as a sterile, aqueous solution for injection administered via either the subcutaneous or intravenous route.

Epoetin Alfa is defined as a biologic medicine—specifically, a recombinant human erythropoietin (rhEPO). This glycoprotein hormone is a man-made version of the endogenous erythropoietin naturally produced in the human kidney. Its production utilizes sophisticated recombinant DNA technology, resulting in a protein structure that is functionally identical to the body’s natural hormone. Epoetin Alfa products are utilized to stimulate red blood cell production in patients whose bodies cannot produce enough of the natural hormone.

What is the General Therapeutic Purpose of Эральфон?

The overall general purpose of Эральфон is to combat and manage anemia, a condition marked by a deficiency of circulating red blood cells or hemoglobin (Hb) levels. The active compound works by binding to the Erythropoietin Receptor on precursor cells in the bone marrow, thus stimulating erythropoiesis (red blood cell formation).

Erythropoiesis-stimulating agents are vital for raising hemoglobin levels in various anemic conditions. By stimulating the production of new red blood cells, Эральфон increases the total oxygen-carrying capacity, thereby addressing the fatigue and weakness associated with anemia. This targeted approach is fundamentally different from nutritional supplements, as it addresses the underlying hormonal signal required for cell production.

Advertisements

What side effects are possible with Эральфон?

Possible Side Effects and Safety Information

Эральфон (Epoetin Alfa) is associated with an official safety profile categorized by frequency and system involvement, as documented by government regulatory authorities.


Adverse Reaction Frequency

The most frequently observed adverse reactions, aligning with the EMA Summary of Product Characteristics, include those affecting the cardiovascular and nervous systems:

  • Very Common (ge 1/10): Arterial Hypertension (high blood pressure) and Headache.
  • Common (ge 1/100 to < 1/10): Thrombotic vascular events (such as deep vein thrombosis or stroke), Rash, and Influenza-like illness.
  • Rare (ge 1/10,000 to < 1/1,000): Serious events such as Pure Red Cell Aplasia (PRCA) and Hypertensive crisis.

Serious Safety Considerations

The most serious adverse reactions documented in regulatory labeling primarily involve the vascular and blood systems. These include thrombotic events, which have a heightened risk, especially when hemoglobin concentration targets are rapidly increased or exceeded, and the rare but severe blood disorder PRCA.

Contextual and Population Safety Notes

Safety notes specify that the risk profile changes based on patient context. The medication is contraindicated in individuals with uncontrolled hypertension. Furthermore, regulatory information highlights an increased risk of thrombotic events in patient populations with Chronic Kidney Disease and those with malignancy. The potential for Influenza-like illness is officially noted as being more common at the start of treatment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The official regulatory profile for an overdose of Эральфон (Epoetin alfa), an erythropoiesis-stimulating agent, is defined by the consequences of its exaggerated therapeutic effect, not by acute toxicity.

Documented Manifestations and Serious Outcomes

Overdose primarily results in excessive erythropoiesis, leading to abnormally high levels of hemoglobin and hematocrit (polycythemia or erythrocytosis). This condition increases blood viscosity and is associated with serious, life-threatening outcomes, including:

  • Stroke and other serious cerebrovascular events.
  • Myocardial Infarction (heart attack).
  • Thromboembolism (blood clots).

Required Emergency Actions and Monitoring

The need for urgent medical intervention is dictated by the patient's hemoglobin level and the rate at which it rises. Regulatory documents specify that immediate action is necessary to reduce the risk of severe complications if hemoglobin approaches or exceeds the target range (e.g., 11 g/dL for adult Chronic Kidney Disease patients).

Immediate Actions:

  • Withholding or reducing the dose of Epoetin alfa is the primary intervention.
  • Therapeutic Phlebotomy (blood withdrawal) may be required to quickly lower the red blood cell mass.

There is no specific pharmacological antidote listed in the official labeling. Management focuses entirely on monitoring the patient closely and reducing the hemoglobin level to mitigate the severe cardiovascular risks.

Advertisements

Therapeutic Uses of Эральфон

What Эральфон Treats: Main Uses and Benefits

The medication Эральфон is applied across domains where additional symptomatic support is needed to help manage symptoms related to chronic anemia. This therapeutic approach is relevant in contexts marked by increased discomfort or tension.

This treatment is commonly used across conditions characterized by periods of heightened symptoms, specifically anemia associated with chronic illnesses like kidney disease, or as a result of certain treatments, such as chemotherapy.

Relieving Fatigue and Enhancing Function

Эральфон addresses symptom clusters that may become intense or disruptive, helping to ease the pronounced fatigue, weakness, and overall lack of energy that interfere with daily functioning. It also may assist with managing physical symptoms that create noticeable physiological strain, such as dizziness, lightheadedness, and shortness of breath during routine exertion.

“This therapy generally contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability.”

A relevant benefit is that this supportive care may assist with reducing the need for blood transfusions, which supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Fatigue and Weakness Эральфон is relevant for easing symptoms related to systemic imbalance, helping patients cope more steadily with chronic tiredness and supporting general well-being during symptomatic phases.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Эральфон (Epoetin Alfa)

The use of Эральфон is strictly governed by regulatory classifications detailing allowed and prohibited populations. The medicine is indicated for patients with anemia due to Chronic Kidney Disease (CKD), including children mathbfgeq 1 month old, and for certain patients with anemia related to myelosuppressive chemotherapy for non-myeloid malignancies. A key condition for use in all eligible populations is the establishment of adequate iron stores, such as a Serum Ferritin level mathbfgeq 100 mcg/L, as stated in labeling.


Populations for Whom Use is Contraindicated

The medicine is contraindicated (absolutely prohibited) for several groups. This includes patients with uncontrolled hypertension and those with a history of Pure Red Cell Aplasia (PRCA) following prior treatment with any erythropoietin protein drug. Furthermore, the multi-dose vial formulation is explicitly contraindicated for use in neonates, infants, pregnant women, and lactating women due to the presence of benzyl alcohol in the preservative.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Эральфон (Epoetin Alfa) confirms the absence of documented pharmacokinetic interactions involving common metabolic pathways, such as the Cytochrome P450 (CYP) enzyme system or drug transporters.


Documented Interaction Patterns

Category Interacting Substance/Condition Official Regulatory Description
Therapeutic Dependency Iron, Folic Acid, Vitamin B12 Inadequate levels of these co-factors are officially documented as causing a lack of therapeutic response to the product. Adequate stores must be ensured for efficacy.
Pharmacodynamic Effect Androgens (e.g., Testosterone) Co-administration may result in a pharmacodynamic additive effect, potentially increasing the overall red blood cell stimulation.
Co-Medication Monitoring Cyclosporine Official labeling requires close monitoring of Cyclosporine blood levels in co-administered patients, as Epoetin Alfa may alter its concentrations.

Regulatory Summary

No medicinal products are explicitly labeled as contraindicated due to a drug-drug interaction with Epoetin Alfa. Furthermore, official labeling does not mandate any specific timing-based separation rules for co-administration. The most critical regulatory constraints concern managing the nutrient-dependent nature of the therapeutic effect and the required blood level monitoring for specific co-medications like Cyclosporine.

Advertisements

Mechanism of Action

Эральфон (Eralfon), a recombinant human erythropoietin (rhEPO) product, functions as an erythropoiesis-stimulating agent (ESA) by mimicking the activity of the endogenous glycoprotein hormone erythropoietin.

The mechanism begins with binding to the erythropoietin receptor (EPO-R), which is expressed on the surface of erythroid progenitor cells in the bone marrow. This interaction induces a conformational change in the receptor, leading to the dimerization of the EPO-R and the subsequent activation of the associated intracellular kinase, Janus family tyrosine protein kinase 2 (JAK2).

Activated JAK2 initiates a downstream signal transduction cascade, primarily involving the STAT5 (Signal Transducer and Activator of Transcription 5) pathway. Phosphorylated STAT5 proteins dimerize, translocate to the cell nucleus, and act as transcription factors to regulate the expression of specific target genes.

This gene activation program promotes the survival, proliferation, and terminal differentiation of erythroid progenitor cells into mature red blood cells (erythrocytes). The system-level consequence is the modulation of circulating erythrocyte mass.

Advertisements

Dosage and Administration Information

Administration Scope

Эральфон, which contains Epoetin Alfa, is administered exclusively by injection. The approved routes are the subcutaneous (SC) route and the intravenous (IV) route. The IV route is typically reserved for patients receiving hemodialysis. The active ingredient is measured and dosed in International Units (IU).

Official Dosing and Scheduling Principles

The high-level approach to using this medication is defined by two distinct periods: an initial correction phase and a long-term maintenance phase. Dosing is highly individualized and primarily relies on a weight-based calculation (IU/kg) derived from the patient's body weight, though fixed-dose regimens are also authorized. For instance, a common starting dose for anemia associated with Chronic Kidney Disease is 50 IU/kg administered three times per week. Other schedules, such as once weekly, are utilized based on the specific context.

Titration and Handling Constraints

A critical procedural rule is dose titration: the dosage and frequency must be adjusted if the rate of hemoglobin increase exceeds specified limits. The dose is reduced if the hemoglobin level rises too rapidly, ensuring the maintenance of the therapeutic range. In terms of physical handling, the official instructions prohibit vigorous shaking of the solution before use, as this may degrade the protein structure. The solution must not be mixed with any other drug products, and any unused portion from a single-use container must be promptly discarded. This protocol ensures the medicine’s integrity and standardization of use.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of Studies for Эральфон

Evidence from Studies in Major Anemia Contexts

A substantial body of research, including large, multi-center Randomized Controlled Trials (RCTs) and comprehensive meta-analyses, has been conducted to explore the use of Эральфон for individuals with anemia related to chronic kidney disease (CKD). The research primarily examined key physical markers such as hemoglobin and hematocrit levels, seeking to determine how these values evolved during the study periods. Findings described patterns observed in the studies related to the evolution of red blood cell count and data show patterns related to transfusion requirements in the observed populations. Regulatory analyses have focused heavily on the potential association with cardiovascular and thrombotic event data when higher target hemoglobin levels are pursued.

For patients experiencing anemia due to chemotherapy, research focused on the requirement for red blood cell transfusions and patient-reported outcomes describing perceived discomfort, primarily relating to cancer-related fatigue. Similar research was also evaluated in more specific clinical situations, such as anemia associated with Zidovudine therapy in HIV-infected patients and studies monitoring transfusion needs during major elective orthopedic surgery. In all contexts, research examines overall survival and the incidence of thromboembolic events (blood clots).

Long-Term Evidence and Research Uncertainty

Clinical trials supporting the main uses often focus on studies observing responses over defined time intervals, meaning long-term effects are not fully established based on the initial, controlled trials alone. Long-term data are still emerging from regulatory surveillance to understand how patterns evolve over many years.

The body of research has explored outcomes in specialized groups like children with CKD, though sample sizes were modest in the primary pediatric trials. Certainty remains low in areas such as optimal management strategy for hemoglobin targets, and research continues to examine data related to survival and tumor progression in specific cancer patient subgroups.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Эральфон (FAQ)

Q: How long must one take Eralfon to see an effect?

Official product information indicates that the first measurable change is usually an increase in reticulocytes (immature red blood cells) within about 10 days of starting therapy.

A noticeable increase in hemoglobin and hematocrit levels typically follows, which is generally observed within 2 to 6 weeks after the start of treatment.


Q: Does Eralfon affect blood or urine tests?

The primary function of this medication is to increase red blood cells and hemoglobin, which are the blood parameters primarily being monitored during treatment.

Additionally, regulatory labeling advises that the drug may alter the blood concentration of certain co-medications, such as Cyclosporine, which requires careful monitoring of those levels.


Q: If I have an allergy, can I use Eralfon?

According to official regulatory documents, this medicine is contraindicated (absolutely prohibited) for patients who have had a serious allergic reaction to Epoetin Alfa or any of its ingredients.

Serious, whole-body allergic reactions, including anaphylaxis, have been reported with this class of medication.


Q: What does the phrase "limited clinical data" mean?

This phrase, or similar ones like "modest sample sizes," indicates that the research supporting the use of the drug in a specific population was based on a smaller number of participants.

It means that while the drug is officially approved for that group, the data collected from the initial trials may have a lower degree of certainty regarding some long-term clinical outcomes compared to larger studies.


Q: What is the color of Eralfon tablets?

Eralfon is not available as a tablet. It is an aqueous solution for injection administered intravenously or subcutaneously.

The solution itself is officially described in regulatory documents as sterile, clear, and colorless.


Q: Is Eralfon taken before, during, or after a meal?

Because this medication is administered by subcutaneous (under the skin) or intravenous (into the vein) injection, there are no specific regulatory requirements regarding its administration time relative to food or mealtimes.


Q: Is it true that Eralfon is used in sports medicine?

Eralfon is classified as an Erythropoiesis-Stimulating Agent (ESA) because its mechanism increases the body's red blood cell count.

Due to this action, its use is prohibited in competitive sports by regulatory anti-doping organizations worldwide, such as the World Anti-Doping Agency (WADA).


Q: How long does a single dose of Eralfon last?

The duration a dose stays in the body is measured by its half-life, which is the time it takes for half of the drug to be eliminated from the body.

Official information states the half-life following intravenous injection is typically between 4 and 13 hours in adults with chronic kidney disease, but it may be longer following a subcutaneous injection.


Q: Does Eralfon contain lactose or other allergens?

Regulatory documents list the full inactive ingredients, which commonly include Polysorbate 80, Sodium Chloride, and Sodium Phosphate.

Some multi-dose formulations may contain the preservative Benzyl Alcohol. The use of formulations containing Benzyl Alcohol is officially contraindicated in neonates and pregnant or lactating women.


Q: Is it true that Eralfon can affect sleep?

Official regulatory summaries for Epoetin Alfa products have reported insomnia (difficulty sleeping) as a potential adverse reaction in clinical trial or post-marketing data.

However, this effect is not classified among the most frequently observed side effects.


Q: Does Eralfon have contraindications for the elderly?

Official labeling does not list advanced age itself as a contraindication. However, regulatory documents advise that the initial dose selection for elderly patients should be cautious.

This is due to the greater statistical frequency of age-related declines in function (like kidney or heart function) in this population.


Q: What to do if one missed a dose of Eralfon?

Official instructions regarding missed doses are not provided in the main professional labeling, as dosing schedules vary widely by patient.

Decisions on when to take the next dose are best determined through consultation with a healthcare provider.


Q: They say that Eralfon can cause dizziness, is that true?

Yes, official regulatory documents list dizziness (vertigo) as a potential side effect associated with the use of Epoetin Alfa products.

This is described as a less frequent adverse reaction and is not among the 'Very Common' side effects like headache or high blood pressure.


Q: Is it necessary to change one's diet when taking Eralfon?

The effectiveness of the medication relies heavily on having adequate internal stores of co-factors like Iron, Folic Acid, and Vitamin B12.

Official regulatory warnings emphasize that these stores must be ensured before and during treatment, often requiring nutritional adjustments or supplementation.


Q: Can one drive a car during the course of Eralfon?

Regulatory documents advise that the ability to drive and use heavy machinery may be negatively affected by the occurrence of certain documented side effects.

These include common reactions such as headache or hypertension, as well as rare, serious effects like seizures.


Q: Can one stop taking Eralfon on their own if they feel better?

Official regulatory instructions emphasize that the dosage and treatment schedule must be determined and managed by a doctor.

Discontinuation or change in dose should only occur after consultation with a healthcare provider.


Q: What happens if one takes too much Eralfon?

Official product labeling states that an overdose can lead to an exaggeration of the drug's intended action.

This can result in polycythemia (excessively high red blood cell counts) and an increased risk of severe cardiovascular complications. Regulatory documents state that management of an overdose requires the direct attention of a healthcare professional, often involving temporary withholding of the drug.


Q: Can Eralfon affect mood or emotional state?

While not common, some Epoetin Alfa product regulatory summaries have listed effects related to emotional state, such as anxiety, in the list of less common adverse reactions.

Official documentation describes these under the category of psychiatric disorders.


Q: What is the main difference between Eralfon and generics?

Eralfon's active ingredient, Epoetin Alfa, is a biologic medicine, meaning it is made from living cells. Its biological equivalents are known as biosimilars (the equivalent of generics for biologics).

Biosimilars are approved based on evidence demonstrating they have no clinically meaningful differences in safety and effectiveness compared to the reference product.


Q: Can Eralfon cause insomnia?

Yes, trouble sleeping (insomnia) has been reported in post-marketing or clinical trial data for Epoetin Alfa products.

However, official labeling does not list it among the most frequently observed side effects.

Advertisements

How should Эральфон be stored and disposed of?

The official labeling for Эральфон (Epoetin Alfa) dictates specific conditions essential for maintaining product stability, as it is a biologic protein solution. The unopened solution must be stored refrigerated at 2 C to 8 C (36 F to 46 F) and must be kept in its original outer carton until use to protect it from light. The solution must not be frozen or vigorously shaken, as this can inactivate the protein. The product must be stored out of the sight and reach of children. Single-dose vials must be discarded immediately after use. Unused contents of preserved multiple-dose vials must be refrigerated and discarded 21 days after the initial entry. All used syringes and expired medication must be disposed of in accordance with local regulatory requirements for medical and sharps waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Эральфон found in:

A-Z Index: